The TyVAC Economics Program is a comprehensive set of policy research activities including cost of illness (COI) studies, cost of delivery studies, household catastrophic expenditure assessments, and cost-effectiveness analyses (CEAs).Read More >
What We Do
The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Our Approach Blends
- Rigorous science
- Productive partnership
- Clear communication
- Capacity building and training
Our Practice Areas
Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.
Coverage & Equity
To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.
Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.
To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.
Economics & Finance
To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.
To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.
To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.
As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.
To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.
We hypothesize that complete and timely vaccinations in early childhood contributes towards improvements in early cognitive development and educational attainment, and we plan to study this association. For our pilot study, children aged 18 months to 8 years will be enrolled based on age categories, and assessed for cognition scores, adaptive behavior, and immunization status at baseline.Read More >
Data on the economic value of these investments can help decision-makers compare the benefits of vaccination with other health and non-health investments. These data can also provide advocates with rigorous evidence to demonstrate the impact of vaccines in terms that are comparable with other sectors.Read More >
VIEW-hub is IVAC’s publicly accessible interactive platform to visualize real-time information on vaccine use, product type, coverage levels, impact assessments, and disease burden estimates. It can be utilized to track progress and strategize ways to accelerate and optimize vaccine implementation.Read More >